BOverview
Biodesix develops diagnostic tests and related services powered by proprietary AI platforms to address clinical unmet needs, mainly in lung disease. It discovers, develops, and commercializes data-driven diagnostic solutions that help healthcare providers choose effective treatments. The products work by analyzing complex biological data to produce accurate diagnostic readouts that inform patient care, while partnerships with hospitals and research institutions expand implementation. Unlike many competitors, Biodesix emphasizes an AI-driven, data-centric approach and end-to-end involvement from discovery to commercialization, with a focus on reducing unnecessary treatments and lowering overall healthcare costs. The company’s goal is to improve patient outcomes by delivering precise diagnostics that guide better treatment decisions.
Work here?Claim your company
About Biodesix
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
201-500
Company Stage
IPO
Headquarters
Louisville, KY
Founded
2005
Get referred to Biodesix
See people who can refer or advise you
Funding
Total Funding
$388.7M
Below
Industry Average
Funded Over
19 Rounds
Benefits
- Health Insurance
- Dental Insurance
- Vision Insurance
- Disability Insurance
- Life Insurance
- Health Savings Account/Flexible Spending Account
- Paid Vacation
- Paid Sick Leave
- Paid Holidays
- Employee Assistance Program
- Voluntary Benefits
Stock Price
Company News
Biodesix (NASDAQ:BDSX) stock price breaks below 200-day moving average - Here's what happened. Shares of Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $18.90 and traded as low as $7.96. Biodesix shares last traded at $8.53, with a volume of 1,586,239 shares trading hands. More Biodesix news. Here are the key news stories impacting Biodesix this week: * Biodesix plans to end 2026 with approximately 115 sales representatives, an effort to expand its commercial reach. * Third-quarter revenue was $24.04 million, below analysts' estimate of $27.49 million. Biodesix reported a loss of $0.75 per share; one cited consensus was $0.75, while Zacks reported a $0.74 estimate. * For 2026, the company forecast revenue of $101 million to $103 million, below the $111.7 million analyst consensus - signaling a weaker outlook than investors had expected. * Biodesix disclosed the departure of Chief Commercial Officer Ki...; the leadership change may add uncertainty as the company works to grow sales. * Following the sharp decline, Johnson Fistel said it had opened an investigation into whether Biodesix or its officers made misleading statements or failed to disclose material information. This is an investigation, not a finding of wrongdoing. Wall street analyst weigh in. A number of research firms have commented on BDSX. Weiss Ratings upgraded Biodesix from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, September 8th. TD Cowen reissued a "buy" rating and set a $40.00 price objective (up from $30.00) on shares of Biodesix in a research report on Tuesday, October 13th. HC Wainwright reissued a "buy" rating on shares of Biodesix in a report on Thursday, October 22nd. Finally, Canaccord Genuity Group increased their price target on Biodesix from $27.00 to $35.00 and gave the stock a "buy" rating in a research note on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Biodesix currently has an average rating of "Moderate Buy" and an average target price of $36.25. Biodesix stock down 57.0%. The company has a debt-to-equity ratio of 5.12, a current ratio of 2.85 and a quick ratio of 2.85. The firm has a 50-day moving average of $25.53 and a 200 day moving average of $18.90. The stock has a market capitalization of $89.99 million, a price-to-earnings ratio of -3.09 and a beta of 0.65. Biodesix (NASDAQ:BDSX - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.75) earnings per share for the quarter, meeting the consensus estimate of ($0.75). The company had revenue of $24.04 million during the quarter, compared to analysts' expectations of $27.49 million. Biodesix had a negative return on equity of 788.19% and a negative net margin of 26.97%. As a group, sell-side analysts forecast that Biodesix, Inc. will post -2.68 earnings per share for the current fiscal year. Insider buying and selling. In other Biodesix news, Director Jack Schuler acquired 15,000 shares of the company's stock in a transaction dated Wednesday, August 12th. The shares were purchased at an average cost of $24.47 per share, for a total transaction of $367,050.00. Following the completion of the purchase, the director owned 555,810 shares in the company, valued at approximately $13,600,670.70. This trade represents a 2.77% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have acquired a total of 42,600 shares of company stock worth $1,033,062 in the last three months. 23.20% of the stock is owned by company insiders. Institutional inflows and outflows. Several large investors have recently bought and sold shares of BDSX. Allworth Financial LP bought a new position in Biodesix in the second quarter worth about $112,000. Walleye Capital LLC acquired a new position in Biodesix in the 1st quarter valued at $157,000. Renaissance Technologies LLC acquired a new stake in Biodesix during the 1st quarter worth approximately $173,000. Cetera Investment Advisers grew its stake in Biodesix by 20.0% in the first quarter. Cetera Investment Advisers now owns 12,000 shares of the company's stock valued at $174,000 after acquiring an additional 2,000 shares during the period. Finally, Squarepoint Ops LLC bought a new stake in shares of Biodesix in the second quarter valued at $354,000. Hedge funds and other institutional investors own 20.96% of the company's stock. About Biodesix. Biodesix, Inc is a data-driven diagnostic solutions company focused on improving the diagnosis and treatment of lung diseases, including lung cancer. The company combines proprietary molecular diagnostic technologies, clinical data, and artificial intelligence to help physicians assess disease risk and make more informed treatment decisions. Its offerings include blood-based tests designed to help evaluate indeterminate pulmonary nodules, identify patients who may be at higher risk of lung cancer, and support treatment selection and monitoring. Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.
Law firm Johnson Fistel is investigating whether Biodesix (NASDAQ: BDSX), a Colorado-based diagnostic solutions company, or its officers made false or misleading statements to investors. The probe follows a share drop of more than 50% during intraday trading on November 6, 2026. On November 5, 2026, Biodesix reported third-quarter revenue of $24.0 million. It cut its full-year 2026 revenue guidance to $101 million to $103 million, down from $108 million to $114 million. The company blamed weak growth partly on sales force challenges, including staffing issues. Johnson Fistel, a shareholder rights firm, encourages investors who lost money on Biodesix securities to contact it.
Biodesix (BDSX) shares plunge; Johnson Fistel's Colorado office initiates investigation on behalf of investors. SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) - Johnson Fistel, PLLP, a national shareholder rights law firm with an office in Denver, Colorado, has begun investigating potential securities claims on behalf of Biodesix, Inc. (NASDAQ: BDSX) investors following the Company's sharp stock decline on November 6, 2026. The investigation concerns whether Biodesix, a Louisville, Colorado-based diagnostic solutions company, or its officers made materially false or misleading statements or failed to disclose material information to investors. What if I purchased Biodesix securities? If you purchased Biodesix securities and suffered losses, contact Johnson Fistel to learn more about the investigation and your potential legal options. Individuals with information relevant to the investigation are also encouraged to contact the firm. You may also contact Jim Baker at [email protected] or (619) 814-4471. There is no cost or obligation to you. What prompted the investigation? On November 5, 2026, Biodesix reported third-quarter revenue of $24.0 million and reduced its full-year 2026 revenue guidance to $101 million to $103 million, down from its prior guidance of $108 million to $114 million. The Company attributed its disappointing growth in part to challenges involving its sales force, including staffing issues. Following these disclosures, Biodesix shares declined more than 50% during intraday trading on November 6, 2026. Who Is Johnson Fistel, PLLP? Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm's Colorado office is located in Denver. Johnson Fistel represents individual and institutional investors in shareholder derivative and securities class action lawsuits. The firm also represents foreign investors who have purchased securities on U.S. exchanges. Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content. Johnson Fistel, PLLP 501 W. Broadway, Suite 800 San Diego, CA 92101 James Baker | (619) 814-4471 [email protected] https://www.johnsonfistel.com/
Why Cloudflare shares are trading higher by around 15%; Here are 20 stocks moving premarket. by Avi Kapoor Benzinga Staff Writer Stock score locked: want to see it? Benzinga Edge Rankings give you vital metrics on any stock - anytime. Shares of Cloudflare, Inc. (NYSE:NET) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results. Cloudflare reported third-quarter revenue of $782.513 million, up 39% year-over-year. The revenue total beat a Street consensus of $738.532 million, according to data from Benzinga Pro. The company reported earnings of 38 cents per share for the quarter, beating a Street consensus estimate of 34 cents per share. Cloudflare shares jumped 14.6% to $281.00 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers. * Redcloud Holdings PLC (NASDAQ:RCT) gained 122.7% to $0.067 in pre-market trading after the London-based technology and B2B open commerce platform announced a new integration agreement in Argentina. * Tianci International Inc (NASDAQ:CIIT) jumped 71.6% to $2.66 in pre-market trading following the Hong Kong-based ocean freight forwarder's announcement of fiscal 2026 results * VisionSys AI Inc. (NASDAQ:VSA) gained 51.4% to $2.3320 in pre-market trading after declining 7% on Thursday. * SHF Holdings, Inc. (NASDAQ:SHFS) rose 48% to $0.0395 in pre-market trading after declining 16% on Thursday. * JFrog Ltd. (NASDAQ:FROG) climbed 21.3% to $90.50 in pre-market trading after the company reported better-than-expected third-quarter financial results and issued fourth-quarter guidance above estimates. Advertisment * Eton Pharmaceuticals, Inc. (NASDAQ:ETON) gained 19.8% to $56.50 in pre-market trading after the company reported better-than-expected third-quarter financial results and issued FY26 guidance above estimates. * nLIGHT, Inc. (NASDAQ:LASR) gained 17.3% to $34.42 in pre-market trading after the company reported better-than-expected third-quarter financial results and issued current-quarter sales guidance above estimates. * IREN Limited (NASDAQ:IREN) gained 17.1% to $21.11 in pre-market trading after the company reported better-than-expected quarterly sales results. * SharonAI Holdings Inc. (NASDAQ:SHAZ) rose 8.6% to $21.25 in pre-market trading after dipping 20% on Thursday. Losers. * Site Centers Corp (NYSE:SITC) fell 81.5% to $0.66 in pre-market trading after declining 4% on Thursday. * Biostem Technologies Inc (NASDAQ:BSEM) fell 54.1% to $0.48 in pre-market trading. BioStem Technologies will host third quarter financial results conference call on Nov. 12. * Antelope Enterprise Holdings Ltd (NASDAQ:AEHL) fell 38.4% to $10.74 in pre-market trading after jumping 178% on Thursday. * Biodesix Inc (NASDAQ:BDSX) fell 36.4% to $12.60 in pre-market trading after the company reported third-quarter 2026 financial results and lowered its full-year revenue guidance to be between $101 million and $103 million. * Baird Medical Investment Holdings Ltd (NASDAQ:BDMD) fell 34.7% to $0.10 in pre-market trading after the company announced that its strategic partner, Alpmed, had submitted regulatory applications in the U.S. and European Union for an irreversible electroporation (IRE) system. * Lakewood-amedex Biotherapeutics Inc (NASDAQ:LABT) tumbled 23.7% to $0.41 in pre-market trading. Lakewood-Amedex Biotherapeutics shares jumped 182% on Thursday after the company announced it completed the redemption of all remaining outstanding shares of its Series C Convertible Preferred Stock. * NetClass Technology Inc (NASDAQ:NTCL) shares declined 22.2% to $0.25 in pre-market trading after falling 15% on Thursday. NetClass Technology announced a $1.2 million registered direct offering of 3 million shares at $0.40/share. * DraftKings Inc (NASDAQ:DKNG) fell 20.6% to $18.65 in pre-market trading after the company reported worse-than-expected quarterly financial results and cut its FY26 sales guidance below estimates. * Nerdwallet Inc (NASDAQ:NRDS) declined 17.6% to $9.40 in pre-market trading after the company reported worse-than-expected quarterly financial results. * Five9 Inc (NASDAQ:FIVN) declined 16.9% to $28.38 in pre-market trading after the company reported third-quarter financial results and cut its FY26 adjusted EPS guidance below estimates.
Biodesix reported third-quarter 2026 revenue of $24 million, up 10% from $21.8 million a year earlier, but said the result fell short of its expectations. The lung diagnostics company cut its full-year revenue forecast to $101 million to $103 million. Chief executive officer Scott Hutton blamed execution and timing rather than weaker demand. A smaller-than-planned sales force, seasonal patterns in primary care and delayed customer projects weighed on results. Test volume grew 24% to about 19,400, and diagnostic testing revenue rose 16% to $23 million. Net loss narrowed 8% to $8 million. The company had $28.4 million in cash at quarter end. It now has about 110 sales representatives and plans to reach about 115 by year end.
Biodesix is Hiring for 27 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
About Biodesix
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
201-500
Company Stage
IPO
Headquarters
Louisville, KY
Founded
2005
Biodesix is Hiring for 27 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs